Recent

% | $
Quotes you view appear here for quick access.

CytRx Corporation Message Board

  • ijob11 ijob11 Jul 29, 2011 10:52 AM Flag

    Current Clinical Trials

    For the remainder of the year:

    Estimated Study Completion Date: December 2011
    Estimated Primary Completion Date: August 2011
    Hormone Refractory Prostate Cancer
    Drug: Bafetinib
    Phase II

    Estimated Study Completion Date: October 2011
    Estimated Primary Completion Date: October 2011
    Malignant Solid Tumour
    Drug: INNO-206
    Phase I

    Estimated Primary Completion Date: December 2011
    Acute Promyelocytic Leukemia
    Drug: Tamibarotene
    Phase II

    Estimated Primary Completion Date: December 2011
    B-Cell Chronic Lymphocytic Leukemia
    Drug: bafetinib
    Phase II

    imo, any Phase III would begin in 2012 since only one, a Phase II, is estimated to complete by eoy. This is bleak and yet promising since all three drugs have shown efficacy.

    ======

    Data for current clinical trials:
    B-Cell Chronic Lymphocytic Leukemia
    Drug: bafetinib
    Phase II

    Estimated Enrollment: 20
    Study Start Date: June 2010
    Estimated Study Completion Date: April 2012
    Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)

    ---

    Acute Promyelocytic Leukemia
    Drug: Tamibarotene
    Phase II

    Estimated Enrollment: 50
    Study Start Date: September 2007
    Estimated Study Completion Date: December 2012
    Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)

    ---

    Hormone Refractory Prostate Cancer
    Drug: Bafetinib
    Phase II

    Estimated Enrollment: 49
    Study Start Date: August 2010
    Estimated Study Completion Date: December 2011
    Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)

    ---

    Malignant Solid Tumour
    Drug: INNO-206
    Phase I

    Estimated Enrollment: 24
    Study Start Date: April 2011
    Estimated Study Completion Date: October 2011
    Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)

    ---

    Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion
    Stage IV Non-small Cell Lung Cancer
    Drug: Tamibarotene
    Drug: Placebo
    Phase II

    Estimated Enrollment: 140
    Study Start Date: April 2011
    Estimated Study Completion Date: April 2013
    Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CYTR
0.598-0.004(-0.73%)11:40 AMEDT